Alzheimers disease (AD) is characterized by the presence of senile plaques in the brain and blood vessel walls. Amyloid Beta A4 (Ab4) protein has been found to be the principal constituent of senile plaques of ADs patients. The amyloid beta-protein precursor (APP) is proteolytically cleaved to generate the 4kD Ab4 protein. Two variants of Ab4 can be detected; Ab-40 short-tailed and Ab-42 long-tailed.
Applications
Suitable for use in ELISA. Other applications not tested.
Recommended Dilution
Optimal dilutions to be determined by the researcher.
Storage and Stability
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Immunogen
Synthetic peptide corresponding to the C-terminal (GLMVGGVV) of human beta amyloid peptide 40 (KLH).
Form
Supplied as a lyophilized powder from 0.01M PBS, pH 7.2. Reconstitute in ddH2O to ~1mg/ml.
Purity
Purified by Protein G affinity chromatography.
Specificity
Recognizes the C-terminal of human beta amyloid peptide 40, and full length beta amyloid peptide 40.